JP2021519288A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021519288A5 JP2021519288A5 JP2020551496A JP2020551496A JP2021519288A5 JP 2021519288 A5 JP2021519288 A5 JP 2021519288A5 JP 2020551496 A JP2020551496 A JP 2020551496A JP 2020551496 A JP2020551496 A JP 2020551496A JP 2021519288 A5 JP2021519288 A5 JP 2021519288A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- placebo
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000019695 Migraine disease Diseases 0.000 claims description 7
- 208000002193 Pain Diseases 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 239000000902 placebo Substances 0.000 claims 7
- 229940068196 placebo Drugs 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- TXKRWVMEUQBFSO-UHFFFAOYSA-N sulfuric acid;trihydrate Chemical class O.O.O.OS(O)(=O)=O TXKRWVMEUQBFSO-UHFFFAOYSA-N 0.000 claims 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 206010027603 Migraine headaches Diseases 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 241000251468 Actinopterygii Species 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 239000004067 bulking agent Substances 0.000 claims 1
- 239000002270 dispersing agent Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000000465 moulding Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023116385A JP2023134690A (ja) | 2018-03-25 | 2023-07-18 | Ｃｇｒｐ関連障害のためのリメゲパント |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862647794P | 2018-03-25 | 2018-03-25 | |
| US62/647,794 | 2018-03-25 | ||
| US201862664761P | 2018-04-30 | 2018-04-30 | |
| US62/664,761 | 2018-04-30 | ||
| US201862774285P | 2018-12-02 | 2018-12-02 | |
| US62/774,285 | 2018-12-02 | ||
| US201862777180P | 2018-12-09 | 2018-12-09 | |
| US62/777,180 | 2018-12-09 | ||
| US201862777625P | 2018-12-10 | 2018-12-10 | |
| US62/777,625 | 2018-12-10 | ||
| PCT/US2019/023940 WO2019191008A1 (fr) | 2018-03-25 | 2019-03-25 | Rimegepant pour troubles liés au cgrp |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023116385A Division JP2023134690A (ja) | 2018-03-25 | 2023-07-18 | Ｃｇｒｐ関連障害のためのリメゲパント |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021519288A JP2021519288A (ja) | 2021-08-10 |
| JP2021519288A5 true JP2021519288A5 (fr) | 2021-12-16 |
Family
ID=68060723
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551496A Withdrawn JP2021519288A (ja) | 2018-03-25 | 2019-03-25 | Ｃｇｒｐ関連障害のためのリメゲパント |
| JP2023116385A Pending JP2023134690A (ja) | 2018-03-25 | 2023-07-18 | Ｃｇｒｐ関連障害のためのリメゲパント |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023116385A Pending JP2023134690A (ja) | 2018-03-25 | 2023-07-18 | Ｃｇｒｐ関連障害のためのリメゲパント |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20210000814A1 (fr) |
| EP (2) | EP4088720A1 (fr) |
| JP (2) | JP2021519288A (fr) |
| KR (1) | KR20200135465A (fr) |
| CN (1) | CN112153969A (fr) |
| AU (1) | AU2019242604A1 (fr) |
| BR (1) | BR112020019396A2 (fr) |
| CA (1) | CA3094693A1 (fr) |
| IL (1) | IL277272A (fr) |
| MX (1) | MX2020009856A (fr) |
| PH (1) | PH12020551425A1 (fr) |
| SG (1) | SG11202009199YA (fr) |
| WO (1) | WO2019191008A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200135465A (ko) * | 2018-03-25 | 2020-12-02 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | Cgrp 관련 장애를 위한 리메게판트 |
| US20210338654A1 (en) * | 2019-01-20 | 2021-11-04 | Biohaven Pharmaceutical Holding Company Ltd. | Cgrp antagonists for treating migraine breakthrough |
| KR20220114613A (ko) * | 2019-12-17 | 2022-08-17 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | Cgrp 저해제의 비강내 약제학적 조성물 |
| EP4110337A4 (fr) * | 2020-02-27 | 2024-03-20 | Pfizer Ireland Pharmaceuticals | Forme galénique orale de rimégépant à dispersion rapide |
| EP4126002A4 (fr) * | 2020-03-23 | 2024-04-10 | Pfizer Ireland Pharmaceuticals | Méthodes de traitement d'une lésion pulmonaire avec des inhibiteurs de cgrp |
| IL296872A (en) * | 2020-03-29 | 2022-11-01 | Biohaven Pharmaceutical Ireland Dac | Preventive treatment for migraine |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| US20230285380A1 (en) * | 2021-05-25 | 2023-09-14 | Biohaven Pharmaceutical Ireland Dac | Dual treatment of migraine |
| CN115850266A (zh) * | 2021-09-26 | 2023-03-28 | 奥锐特药业(天津)有限公司 | 瑞美吉泮新晶型及其制备方法 |
| WO2023055758A1 (fr) * | 2021-09-29 | 2023-04-06 | Pfizer Ireland Pharmaceuticals | Traitement préventif de la migraine |
| CN114010608A (zh) * | 2021-11-23 | 2022-02-08 | 莱默(北京)药业科技有限公司 | 一种瑞美吉泮冻干口崩片及制备方法 |
| CN115154469A (zh) * | 2022-07-22 | 2022-10-11 | 中国科学院广州生物医药与健康研究院 | 瑞美吉泮或其药学上可接受的盐在制备预防或治疗肥胖的药物中的应用 |
| WO2024062504A1 (fr) * | 2022-09-22 | 2024-03-28 | Quisitive Therapeutics | Composition pharmaceutique comprenant de l'ubrogépant et son administration |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| GB9817793D0 (en) | 1998-08-14 | 1998-10-14 | Scherer Corp R P | The formation of indicia in the base of a blister pack for transference to a body cast therein |
| US7704583B2 (en) | 1998-08-14 | 2010-04-27 | R.P.Scherer Technologies, Inc. | Embossed blister pack |
| GB9908014D0 (en) * | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| CA2615463A1 (fr) * | 2005-07-29 | 2007-02-08 | Merck & Co., Inc. | Antagonistes des recepteurs de cgrp de benzodiazepine heterocyclique |
| US8715715B2 (en) * | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
| US8314117B2 (en) | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8669368B2 (en) | 2010-10-12 | 2014-03-11 | Bristol-Myers Squibb Company | Process for the preparation of cycloheptapyridine CGRP receptor antagonists |
| DK2820016T3 (da) | 2012-02-27 | 2017-11-13 | Bristol Myers Squibb Co | N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylat, hemisulfatsalt |
| EP2815749A1 (fr) * | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Forme solide de 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione ayant un réseau de diffraction de rayons X spécifique |
| AU2015214502B2 (en) * | 2014-02-05 | 2019-06-06 | Merck Sharp & Dohme Llc | Tablet formulation for CGRP-active compounds |
| CA2921336A1 (fr) * | 2015-06-30 | 2016-12-30 | Gilead Sciences, Inc. | Formulations pharmaceutiques |
| GB201519196D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| KR20200135465A (ko) * | 2018-03-25 | 2020-12-02 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | Cgrp 관련 장애를 위한 리메게판트 |
| US20210338654A1 (en) * | 2019-01-20 | 2021-11-04 | Biohaven Pharmaceutical Holding Company Ltd. | Cgrp antagonists for treating migraine breakthrough |
-
2019
- 2019-03-25 KR KR1020207030358A patent/KR20200135465A/ko unknown
- 2019-03-25 EP EP22182756.1A patent/EP4088720A1/fr active Pending
- 2019-03-25 SG SG11202009199YA patent/SG11202009199YA/en unknown
- 2019-03-25 MX MX2020009856A patent/MX2020009856A/es unknown
- 2019-03-25 EP EP19776794.0A patent/EP3773572A4/fr active Pending
- 2019-03-25 AU AU2019242604A patent/AU2019242604A1/en active Pending
- 2019-03-25 BR BR112020019396-8A patent/BR112020019396A2/pt unknown
- 2019-03-25 WO PCT/US2019/023940 patent/WO2019191008A1/fr unknown
- 2019-03-25 CA CA3094693A patent/CA3094693A1/fr active Pending
- 2019-03-25 JP JP2020551496A patent/JP2021519288A/ja not_active Withdrawn
- 2019-03-25 CN CN201980034240.4A patent/CN112153969A/zh active Pending
- 2019-03-25 US US16/767,134 patent/US20210000814A1/en not_active Abandoned
-
2020
- 2020-05-27 US US16/884,196 patent/US11083724B2/en active Active
- 2020-09-10 PH PH12020551425A patent/PH12020551425A1/en unknown
- 2020-09-10 IL IL277272A patent/IL277272A/en unknown
-
2021
- 2021-08-08 US US17/396,717 patent/US20220168295A1/en not_active Abandoned
-
2023
- 2023-07-18 JP JP2023116385A patent/JP2023134690A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519288A5 (fr) | ||
| US9572781B2 (en) | Orally disintegrating tablet compositions comprising combinations of non-opioid and opioid analgesics | |
| EP2276465B1 (fr) | Formulation à libération prolongée contenant une cire | |
| TW389696B (en) | Accelerated release composition containing bromocriptine | |
| JP5026262B2 (ja) | 経口抗菌医薬組成物 | |
| JP2012144554A (ja) | テトラサイクリンの１日１回製剤 | |
| CN109310642B (zh) | 美沙拉嗪的口服药物组合物 | |
| JP2020527575A5 (fr) | ||
| EP1462098B1 (fr) | Composition pharmaceutique stabilisée comprenant une NSAID et une prostaglandine | |
| JPWO2011102504A1 (ja) | 経口用徐放性固形製剤 | |
| TW201739455A (zh) | 菸鹼醯胺的口服醫藥組成物 | |
| KR101531030B1 (ko) | 미르타자핀 함유 구강붕해정 | |
| MXPA04009906A (es) | Composiciones farmaceuticas de liberacion controlada de carbipoda y levopoda. | |
| EP3925601A1 (fr) | Formulation gastro-résistante contenant du posaconazole et un inhibiteur de précipitation polymère | |
| AU2014326142B2 (en) | Pharmaceutical composition comprising capecitabine and cyclophosphamide | |
| KR20140118412A (ko) | 활성 성분으로 에페리손을 함유하는 서방성 제제 조성물 | |
| JP5962161B2 (ja) | 耳管開放症治療剤 | |
| KR20160105662A (ko) | 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물 | |
| WO2019209217A2 (fr) | Formulations à libération modifiée de flurbiprofène | |
| JP7404828B2 (ja) | 経口医薬製剤およびその製造方法 | |
| JP2018123115A (ja) | 経口固形製剤 | |
| EP4070793A1 (fr) | Composition pharmaceutique, trousse complémentaire et son application | |
| JP6855387B2 (ja) | 圧縮成型製剤 | |
| JP2022042886A (ja) | アビラテロン酢酸エステル含有製剤 | |
| RU2446803C1 (ru) | Лекарственное средство в виде капсул, обладающее противовирусным и интерфероногенным действием |